Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study: 2.5% of Americans have food allergy

An estimated 2.5 percent of Americans — 7.5 million people — have at least one food allergy and young black children with asthma appear to be at the highest risk, according to findings from what is believed to be the largest food allergy study to date. The research was conducted by investigators at Johns Hopkins Children's Center, the National Institutes of Health and other institutions.

18 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

18 Oct 2010

Genmab provides update on potential regulatory pathway for zalutumumab

Genmab A/S announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA.

18 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

Genentech and Biogen Idec announce positive results from ocrelizumab phase II RRMS study

Genentech, Inc., a member of the Roche Group, and Biogen Idec today announced 24-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate.

15 Oct 2010

LifeBridge Health reveals two ways to prevent seasonal flu

You're having that dreaded feeling. Your muscles are aching, you've got a a fever and sore throat . Get ready: It is flu season again! The flu is a respiratory virus that's contagious. In addition to the symptoms above, a, cough and headache, as well as diarrhea may indicate the virus is present.

15 Oct 2010

Scientists discover mechanism of anticancer drug to kill cancer cells

A potent drug derived from an evergreen tree may soon save the lives of some patients with the deadliest form of breast cancer. According to the National Cancer Institute, breast cancer will claim approximately 40,000 lives in the U.S. this year.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Scientists identify mechanism that regulate nuclear size

Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.

15 Oct 2010

NIH awards two new grants to develop Avidocin platform

AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.

15 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Omeros receives additional NIDA grant for clinical studies in Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute.

14 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010